Standard of Care anti-PD-1/PD-L1 (ICI)

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153CADLPhase 2Active not recruiting2024-12-31Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.